ABIM MOC Part 2 • CME

February 3 • 4:00 – 5:00
Advances in CART Therapy for Lymphoma
Natalie Grover, MD

ABIM MOC Part 2 • CME

February 17 • 4:00 – 5:00
The Age of Oncogeriatrics
Ashley E. Rosko, MD

ABIM MOC Part 2 • CME

March 3 • 4:00 – 5:00
Tailoring Treatment Intensity in HNSCC: The Expanding Role of Cancer Immunotherapy
Robert L. Ferris, MD, PhD

Immunotherapy has become integrated into therapy for many solid tumors. As this new modality has evolved through recurrent/metastatic and recently into the locally advanced setting, new insights and dangers have been encountered, providing insights into complex interactions of conventional modalities with immunotherapeutic modulation of the tumor microenvironment and clinical benefit for patients. The roles of treatment intensification and de-intensification using immunotherapy will be discussed.

ABIM MOC Part 2 • CME

March 17 • 4:00 – 5:00
Locoregional Recurrence in ER+ HER2– Breast Cancer: Clinical Reality, Therapeutic Uncertainty, and the Need for Biologic Insight
Meghan Flanagan, MD, MPH

ABIM MOC Part 2 • CME

April 21 • 4:00 – 5:00
ctDNA, Immunotherapy/Biomarkers in Colorectal Cancer
Chris Lieu, MD

ctDNA, Immunotherapy in colorectal Cancer (MSI, MSS), biomarkers in colorectal cancer

ABIM MOC Part 2 • CME

May 5 • 4:00 – 5:00
Sarcoma
Theodore (Ted) Yanagihara, MD, PhD

ABIM MOC Part 2 • CME

May 19 • 4:00 – 5:00

The Emerging Field of Adolescent and Young Adult Oncology Through the Lens of Germ Cell Tumors
Lindsay Frazier, MD, ScM